首页> 外文期刊>Bone marrow transplantation >Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
【24h】

Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.

机译:降低强度的同种异体移植后,克隆细胞遗传学改变和骨髓瘤复发。

获取原文
获取原文并翻译 | 示例
           

摘要

To identify a correlation between metaphase cytogenetics and relapse after reduced intensity conditioning (RIC) allotransplant for patients with multiple myeloma, data on 60 patients (median age 52) who received grafts from a sibling (n = 49) or unrelated donor (n = 11) were analyzed. Fifty-three patients (88%) showed chromosomal abnormalities (CA) before the allotransplant, including 42 with abnormalities involving 13q (CA13). Twenty-two patients (41%) relapsed post-allotransplant at a median of 165 days. Of these, 11 patients showed abnormal cytogenetics at the time of post-allotransplant relapse at a median of 167 days. Of 54 patients who developed graft-versus-host disease, relapse occurred in 19 of 48 patients (43%) with CA present before RCI allotransplant, versus 1 of 6 without CA (17%) (P = 0.06). Loss of CA before RIC allotransplant and disease status > PR after RIC allotransplant were significantly associated with a lower risk of post-allotransplant relapse with cytogenetic abnormalities; 5.2vs 36%, and 18 vs 53%, (both P < 0.05), respectively. The current data suggests that myeloma associated with persistent clonal cytogenetic abnormalities is an entity which most likely escapes the effects of a graft versus myeloma activity, maybe because of acquisition of resistance to immunologic manipulations.
机译:为了确定多发性骨髓瘤患者降低强度条件(RIC)同种异体移植后中期细胞遗传学与复发之间的相关性,收集了60例从同胞(n = 49)或无关供者(n = 11)接受移植的患者(中位年龄52岁)的数据)进行了分析。异体移植前有53例患者(88%)出现染色体异常(CA),其中42例涉及13q(CA13)异常。十二指肠移植后复发的患者中位数为165天(41%)。其中11例患者在异种移植后复发时表现出异常的细胞遗传学,中位数为167天。在54例发生移植物抗宿主病的患者中,复发发生在48例RCI同种异体移植前存在CA的患者中(19%),而6例无CA的患者中复发(17%)(P = 0.06)。 RIC同种异体移植前的CA丢失和RIC同种异体移植后的疾病状态> PR与同种异体移植后复发和细胞遗传学异常的风险显着相关。 5.2比36%,分别为18%和53%(均P <0.05)。当前数据表明,与持续性克隆细胞遗传学异常相关的骨髓瘤是最有可能逃脱移植物抗骨髓瘤活性影响的实体,这可能是由于获得了对免疫操作的抗性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号